RxDoctor Payments Data

Gabriela Henriquez, MD

Internal Medicine · Bronx, NYNPI 1083906564

Payments from drug & device makers

$296in general payments, 2019–2025

Across 14 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$76
  • Bayer$62
  • Akebia Therapeutics Inc$41
  • Otsuka America Pharmaceutical, Inc.$25
  • Novo Nordisk$24
  • Mallinckrodt Enterprises LLC$20
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$27894%
  • Education$196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$296 in reported general payments places this provider in the 55th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$114,094
Medicare patients
128
Services billed
645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol376$276,993
LokelmaSodium Zirconium Cyclosilicate166$127,084
XphozahTenapanor Hcl41$112,818
AuryxiaFerric Citrate53$89,277
VelphoroSucroferric Oxyhydroxide25$51,858
VeltassaPatiromer Calcium Sorbitex34$41,582
Sevelamer Hcl15$20,375
Sevelamer Carbonate114$17,887
TradjentaLinagliptin24$12,715
KerendiaFinerenone16$12,636
DapagliflozinDapagliflozin Propanediol15$8,401
Calcium Acetate42$2,704
Nifedipine ErNifedipine116$2,201
Calcitriol36$434
Gentamicin Sulfate15$341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$76$404,077542 claims
Akebia Therapeutics IncAuryxia$41$89,27753 claims
Fresenius USA Marketing, Inc.Velphoro$17$51,85825 claims
Boehringer IngelheimTradjenta$19$12,71524 claims
BayerKerendia$62$12,63616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →